We measured the concentration of CD34
High-dose chemotherapy (HDC), with or without total body irradiation, supported by autologous hematopoietic stem cells (HSC), is widely used in the treatment of patients with chemosensitive malignant diseases. [1] [2] [3] Peripheral blood stem cells (PBSC) are now considered as the graft of choice for hematopoietic support after HDC. The progenitor cell population able to reconstitute hematopoiesis in lethally irradiated primates and humans can be identified by the CD34 antigen. 4, 5 Little is known about the immediate fate of HSC after their infusion into the blood stream. They could home to bone marrow quite rapidly by way of a twostep mechanism involving different adhesion molecules. 6, 7 It has been suggested that the CD34 antigen may participate in adhesive interactions between HSC and stromal cells. 8 In murine models, clearance of bone marrow cells from peripheral blood (PB) is known to be rapid and usually complete within 19 h after infusion. 9, 10 The quantity and quality of PBSC required for successful hematologic recovery after HDC are still being debated. 11, 12 Many reports describe the relationship between the number of HSC/kg infused and the rapidity of hematologic recovery under a certain threshold 11, 13, 14 while others fail to find a correlation. 15 Other parameters predicting the rapidity of hematologic recovery include the use of post-transplant colonystimulating factor (CSF), 13, 14 the type of HDC, and the number of mobilizations necessary to obtain 2.5 × 10 6
CD34
ϩ cells/kg. 14 Other studies have demonstrated a better relationship between rapidity of hematologic recovery and some subtypes of HSC bearing specific adhesion molecules. [16] [17] [18] These reports emphasize the importance of rapid homing for fast hematologic recovery.
In this study, we explored in 34 breast cancer patients undergoing HDC and HSC transplant the fate of CD34 ϩ cells in PB by measuring their concentrations at different times after infusion. We then investigated the biological significance of this clearance of CD34 ϩ cells from PB.
Materials and methods

Patients
Between September 1995 and August 1997, 34 patients with poor prognosis breast cancer underwent HDC supported by PBSC at Saint-Luc UCL Academic Hospital.
Hematopoietic support consisted of unpurged peripheral blood stem cells in 22 patients and purified CD34 ϩ cells in 12 patients. All patients gave informed consent for both HDC and PB CD34 ϩ cell determinations. Patient characteristics are summarized in Table 1 . For one patient, complete data concerning CD34 ϩ cells collected during leukaphereses were not available. This patient was excluded from analysis involving the number of CD34 ϩ cells injected.
PBSC collections
All patients received FEC chemotherapy (5-fluorouracil, epirubicin and cyclophosphamide) associated with G-CSF (Filgrastim, recombinant-methionyl human G-CSF; Amgen-Roche, Brussels, Belgium) for mobilizing HSC into PB. G-CSF 5 or 10 g/kg/day was started the day after chemotherapy and discontinued on the 2nd day of leukapheresis. Leukaphereses were started once the white blood cell (WBC) count reached 1 × 10 9 /l. On 3 consecutive days patients underwent leukaphereses using a continuous flow blood cell separator: Cobe Spectra (Cobe, Lakewood, CO, USA) or Fenwall CS 3000 (Baxter, Chicago, IL, USA). The total blood volume processed per leukapheresis was 10 liters at a flow rate of 60 ml/min. The final product, containing 10% dimethyl sulfoxide (DMSO), was frozen and maintained in liquid nitrogen at −160°C. The minimum collection level chosen for hematopoetic rescue after HDC was 1 × 10 6 CD34 ϩ cells/kg.
cell selection was achieved as previously described. 19 Briefly, 7.5 ml of iron-dextran particles conju- Four patients discharged before reaching 50 × 10 9 platelets/l (two at day 14, one at day 23 and one at day 29). gated to murine anti-CD34 antibodies AC 101 (Becton Dickinson, San Jose, CA, USA) was added to the 95 ml leukapheresis product. The bag was rotated for 30 min at room temperature. Cells were washed twice with phosphate-buffered saline solution (PBS) pH 7.2 plus 0.5% human serum albumin (HSA) and 1 mm EDTA. Antibodylabeled suspension was then passed through two separation columns containing an iron/plastic matrix (Amgen Cell Selection Device, Thousand Oaks, CA, USA) in which a strong magnetic field was generated. This step was completely automatic and computer controlled. The columns were then removed from the magnetic field and washed out with PBS plus HSA and EDTA. Cells were collected and cryopreserved.
CD34 analysis
CD34 determination was realized as previously described. 20 Briefly, for immunofluorescence analysis, 1 × 10 6 mononuclear cells (MNC) of PB or leukapheresis products were incubated for 10 min at room temperature with phycoerythrin (PE)-conjugated monoclonal anti-CD34 antibody HPCA-2 (Becton Dickinson) and fluorescein isothiocyanate (FITC)-conjugated isotypic control mouse IgG1 antibodies (Becton Dickinson). After incubation, erythrocytes were lysed with ammonium chloride buffer for 10 min. The cells were spun down at 600 g for 5 min, washed twice with PBS containing 0.1% sodium azide, and resuspended in 500 l PBS. Immunofluorescence analysis was performed using a FACscan (Becton Dickinson) equipped with an argon laser tuned at 488 nm and 0.3 W. Stability of instrumental settings, including color compensation, was checked daily with fluorescent beads (Quantum 26 and 27; Flow Cytometry Standard Corporation, San Juan, CA, USA and CaliBRITE beads, Becton Dickinson). For each test, 100 000 cells were analyzed. In a forward vs side scatter dot plot, a first region was set up to separate nucleated cells from debris. A second region limited by side scatter was set up to limit the analysis to the MNC population. The CD34 ؉ cells were identified and counted on another dot plot FITC/PE gated in both regions. For that purpose, the CD34 ϩ cells were defined simultaneously by highly fluorescent signals for PE and negative signals for FITC. Cell counts and differentials were performed by STKS automated hemocytometer (Coulter Electronics, Hialeah, FL, USA).
Progenitor cell assays
MNC were isolated from heparinized blood samples or from leukapheresis products by density gradient centrifugation over Ficoll-Hypaque (1.077 g/ml; Pharmacia, Uppsala, Sweden), washed once in Hanks' medium containing 10% FCS (Life Technologies, Long Island, NY, USA) and resuspended in Iscove's modified Dulbecco's medium (IMDM). Granulocyte-macrophage colony-forming unit (CFU-GM)-derived colonies were assayed using a single layer agar system, a modification of our previously described technique. 21 Briefly, the layer contained 10 and 20 ng/ml SCF. Triplicate cultures were incubated at 37°C in 5% O 2 , 5% CO 2 and 100% humidity. Colonies were scored on day 14.
High-dose chemotherapy and autologous stem cell transplant
Patients were treated with a STAMP V (CTCb) regimen including carboplatin 800 mg/m 2 , cyclophosphamide 6 g/m 2 and thiotepa 500 mg/m 2 administered by 96 h continuous infusion. 22 Seventy-two hours after the end of chemotherapy, autologous HSC were thawed in a water bath at 37°C and rapidly injected by way of a central venous catheter. PB samples were obtained for CD34 ϩ cells determination . h before and ., 1, 3, 6 and 12 h after infusion. Ten ml of blood were harvested in heparinized tubes at each time point. In addition, . h after infusion a 10 ml heparinized syringe of blood was collected for CFU-GM determination. Patients received G-CSF 5 (PBSC) or 10 (selected CD34 ϩ cells) g/kg daily subcutaneously, from the day after transplant until granulocyte recovery. Complete blood counts were performed daily. Platelet transfusions were administered empirically for platelet counts less than 15 × 10 9 /l or in case of bleeding.
Statistical analysis
Descriptive statistics are presented as the median and range. The rate of CD34 ϩ cell clearance was estimated by the slope of a straight line fitted through the CD34 ϩ cell counts, measured over time with the pre-infusion baseline value subtracted for each patient. The non-parametric Spearman rank correlation was used to test for correlation between the number of CD34 ϩ cells and CFU-GM injected. KaplanMeier survival estimates and log-rank statistics are presented for comparison of hematologic recovery rates between patients who received a lower vs a higher number of CD34 ϩ cells, and a lower vs a higher number of CFU-GM/kg. Further univariate and multivariate analyses were performed using the Cox proportional hazards model. 23 The level of statistical significance is set at 0.05 (two-sided).
Results
Hematopoietic stem cell support
Hematopoietic support consisted of unpurged PBSC in 22 patients and purified CD34 ϩ cells in 12 patients. Median numbers of CD34 ϩ cells/kg and CFU-GM/kg grafted were, respectively, 7.6 × 10 6 (range 0.96-35.3) and 0.8 × 10 6 (range 0.04-5.5). We observed a good correlation between the number of CD34 ϩ cells/kg and the number of CFU-GM/kg infused: Spearman r = 0.65 (P Ͻ 0.001).
Hematopoietic engraftment
All 34 breast cancer patients had hematopoietic engraftment. The hematologic recovery rates were similar between recipients of purged and unpurged cells and they were pooled in the analysis ( Table 1) . As shown in Figure 1 , there is a significant difference in hematologic recovery rates between those who received higher or lower than 7.5 × 10 6 CD34 ϩ cells/kg, and between those who received higher or lower than 0.85 × 10 6 CFU-GM/kg (logrank test, all P Ͻ 0.02).
Peak of stem cells in peripheral blood after infusion
The peak was defined as the highest CD34 ϩ cell concentration observed in each patient, after subtraction of the baseline. In 27 out of 34 patients, the peak was observed at . h after infusion; in the others at 1 h. The median number of CD34 ϩ cells at . h was 4 × 10 6 /l (range 1-31.1). At the same time point, the median number of CFU-GM was 95 × 10 3 /l (range 2-1737). We found a statistically significant correlation between CD34 ϩ cells and CFU-GM determined 30 min after infusion: Spearman r = 0.41 (P = 0.02).
Clearance of CD34
ϩ cells from peripheral blood
The CD34 ϩ cell counts determined ., 1, 3, 6 and 12 h after transplant were plotted against time (Figure 2) . A straight line was fitted for the CD34 ϩ cell counts from . h to 12 h after infusion. Clearance was defined as the slope of this line and expressed as the decrease of CD34 ϩ cell concentration per hour. In univariate analysis, for every unit increase of CD34 ϩ cells (defined as 100 × 10 3 CD34
ϩ cells/l/h) in the 12-h clearance rate, there is a 1.1-to 1.2-fold improvement in the hematologic recovery rates (P р 0.028) ( Table 2 ). The number of CD34 ϩ cells infused was found to be both a confounder and effect modifier in the association between clearance rate and hematologic recovery rate, thus further analyses were performed. Patients were stratified into two groups: those who received Ͻ7.5 × 10 6 and those who received у7.5 × 10 6 CD34 ϩ cells/kg. This level of 7.5 × 10 6 CD34 ϩ cells/kg infused was chosen for stratification because it represented the median dose infused in our patient population and corresponded to a threshold described in the literature for efficient hematologic recovery. 15, 20 After adjusting for age, the number of CD34 ϩ cells/kg infused and purged or unpurged graft in the Cox proportional hazards model, the increase of clearance rate was found to be associated with an improvement in hematologic recovery rates among patients receiving less than 7.5 × 10 6 CD34 ϩ cells/kg: for every unit increase in clearance rate, a 1.5-and 1.8-fold improvement for neutrophils, and 1.5-and 1.7-fold for unsupported platelets, was observed (Table 3) . This relationship is less apparent among patients who received more than 7.5 × 10 6 CD34 ϩ cells/kg (Table 3) . Stage of disease and number of bags of cells infused were also tested in the multivariate model but showed no association with hematologic recovery rates. The slope was then divided into two parts. The first part was defined as concentrations measured from . to 3 h after transplant and the second part as concentrations measured from 3 to 12 h. The first part was interpreted as the rapid phase and the second as the slow phase of clearance. We then determined the physiological importance of these two phases on hematologic recovery. The first part of the slope did not show better correlations with hematologic recovery rates than those observed in the overall slope, though the association is always stronger among those who received less than 7.5 × 10 6 CD34 ϩ cells/kg. Moreover, those who received less than 7.5 × 10 6 CD34 ϩ cells/kg showed better correlations with the second part of the slope (3 to 12 h post infusion) than they do with the entire slope (Table 4 ). In addition, eight patients with very low doses of CD34 ϩ cells/kg injected (Ͻ3 × 10 6 ) were identifed among our patient population. The multivariate analysis for these patients showed an even stronger predictive value of both the entire slope and the second part of the slope on hematol- ogic recovery. However, the results were not statistically significant probably due to the small sample size (data not shown).
Discussion
The immediate fate of HSC after their infusion into PB is not well known. These cells are believed to home specifically to marrow although, according to murine models, they can be trapped in the liver, spleen or lungs. 9, 10, 24 It has been shown that clearance of murine bone marrow cells from PB is rapid and complete within 19 h. 9 Our first aim was to study the fate of HSC in PB after their infusion in humans. For that purpose, we determined CD34 ϩ cell concentrations in PB at multiple time points after transplant. We limited our CD34
ϩ cell determinations to 12 h after transplant based on previous analysis in which we found that after 12 h CD34 ϩ cell counts were so low that their accuracy was doubtful (data not shown). We used our CD34 ϩ cell concentrations over time as a pharmacokinetic curve. Our study is based on the assumption of a bi-compartmental model, 25 the first being the PB and the second the bone marrow microenvironment. The highest concentration of CD34 ϩ cells in PB was observed just after infusion. This peak correlated with the number of CD34 ϩ cells/kg infused. The clearance of CD34 ϩ cells from PB was rapid during the first 3 h after infusion and then slowed down. These observations are in accordance with experimental animal data. Nilsson et al 9 reported that transplanted bone marrow cells into mice were rapidly cleared from PB within the 3 h after injection and almost no cells were detected in PB 19 h after transplant.
The second aim of our study was to understand the biological significance of the clearance of CD34 ϩ cells from PB. The 12 h clearance of CD34 ϩ cells was highly correlated with the rapidity of hematologic recovery, statistically significant in the group of patients receiving less than 7.5 × 10 6 CD34 ϩ cells/kg but less evident in those receiving a higher number of CD34 ϩ cells/kg. There are several explanations for these observations, the most probable being the analogous case of the absence of correlation between hematologic recovery and high-dose HSC injected. Once a threshold is reached, correlations between hematologic recovery and cell dose injected vanish possibly because excess cells infused will not improve engraftment or hematologic recovery rate. We have observed in our patient population a good relationship between hematologic recovery and the cell dose injected. Our patient population is quite homogenous: same tumor type, PBPC mobilization regimens, HDC, use of G-CSF for mobilization and post infusion, and institution. Variables including use of selected or unselected CD34 ϩ cells were tested in multivariate analysis but were not significant. Many authors have found that the number of HSC/kg injected was the best predictor of the duration of cytopenia following HDC, 11, 13, 14 though others have failed to demonstrate this relationship. 15 Other parameters predicting the rapidity of hematologic recovery have been suggested in the literature, including the use of post-transplant CSF, 13, 14 the type of HDC and the number of mobilizations necessary to obtain 2.5 × 10 6 CD34 ϩ cells/kg. 14 In addition to these parameters, we can now include a dynamic parameter when small doses of HSC are injected, namely the clearance of infused cells from PB. A patient population where small doses of HSC/kg are infused is the most difficult to predict in terms of hematologic recovery. Although the measurement of the slope would be difficult to apply in a routine clinical setting, it is indicative of a true biological significance in the clearance of CD34 ϩ cells from PB after infusion. Defining the true biological significance of the clearance of CD34 ϩ cells from PB is more difficult. Recently, two studies have demonstrated the influence of sub-types of the CD34 ϩ cell population bearing some specific adhesion molecules on the rapidity of hematologic recovery after transplant. [16] [17] [18] The number of CD34 ϩ L-selectin ϩ cells and CD34 ϩ CD44 ϩ cells injected highly correlated with hematologic recovery. These studies suggest the role of a rapid HSC homing to achieve adequate and fast hematologic recovery. Linking CD34 ϩ cell clearance from PB to homing is more delicate. Our data do not evaluate HSC homing; indeed, our model has several shortcomings in that respect. Principally, it is an indirect approach and assumes that all HSC engraft in the bone marrow and are not trapped elsewhere. We know from animal studies that this is not true, 9,10 although this aspecific trapping may be ephemeral. 10 It also assumes that CD34 ϩ cells detected in PB at different time points are living cells able to engraft and divide. Therefore, . h after transplant we also performed a clonogenic assay. Correlation of the two results indicates that at least by . h after transplant, circulating CD34 ϩ cells were clonogenic. The mobilization of host HSC by HDC and thus the possibility of pollution of CD34 ϩ cell counts by these HSC was not relevant here, since the pre-infusion baseline value was subtracted for each time point studied. Finally, our patients received the same HDC regimen which can damage endothelial barrier cells, thus affecting the pharmacokinetic model.
In conclusion, our results suggest that rapidity of clearance of CD34 ϩ cells from PB is an independent indicator of hematologic recovery in patients receiving low doses of CD34 ϩ cells but this relationship is masked when the cell dose injected is over a particular threshold. Future projects prompted by this study will analyze the fate of different subtypes of CD34 ϩ cells after their infusion into PB, its influence on hematologic recovery, and the use of closer time points to further improve the measurement of the slope.
